TMDX Valuation

Transmedics Group Inc

Add to Watchlist

Advanced Chart

118.810

-3.07(-2.519%)1D

Overview
Forecast
Valuation
Earnings

TMDX Relative Valuation

TMDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TMDX is overvalued; if below, it's undervalued.

Historical Valuation

Transmedics Group Inc (TMDX) is now in the Fair zone, suggesting that its current forward PS ratio of 6.39 is considered Fairly compared with the five-year average of -12.92. The fair price of Transmedics Group Inc (TMDX) is between 86.45 to 264.63 according to relative valuation methord.

Relative Value

Fair Zone

86.45-264.63

Current Price：118.58

Fair

51.79

Trailing

Forward

31.03

EV/EBITDA

Transmedics Group Inc. (TMDX) has a current EV/EBITDA of 31.03. The 5-year average EV/EBITDA is -7.70. The thresholds are as follows: Strongly Undervalued below -197.69, Undervalued between -197.69 and -102.70, Fairly Valued between 87.30 and -102.70, Overvalued between 87.30 and 182.30, and Strongly Overvalued above 182.30. The current Forward EV/EBITDA of 31.03 falls within the Historic Trend Line -Fairly Valued range.

50.51

EV/EBIT

Transmedics Group Inc. (TMDX) has a current EV/EBIT of 50.51. The 5-year average EV/EBIT is -36.05. The thresholds are as follows: Strongly Undervalued below -299.64, Undervalued between -299.64 and -167.85, Fairly Valued between 95.74 and -167.85, Overvalued between 95.74 and 227.54, and Strongly Overvalued above 227.54. The current Forward EV/EBIT of 50.51 falls within the Historic Trend Line -Fairly Valued range.

6.35

Transmedics Group Inc. (TMDX) has a current PS of 6.35. The 5-year average PS is 10.90. The thresholds are as follows: Strongly Undervalued below -1.11, Undervalued between -1.11 and 4.89, Fairly Valued between 16.90 and 4.89, Overvalued between 16.90 and 22.91, and Strongly Overvalued above 22.91. The current Forward PS of 6.35 falls within the Historic Trend Line -Fairly Valued range.

28.85

P/OCF

Transmedics Group Inc. (TMDX) has a current P/OCF of 28.85. The 5-year average P/OCF is 47.74. The thresholds are as follows: Strongly Undervalued below -357.50, Undervalued between -357.50 and -154.88, Fairly Valued between 250.36 and -154.88, Overvalued between 250.36 and 452.98, and Strongly Overvalued above 452.98. The current Forward P/OCF of 28.85 falls within the Historic Trend Line -Fairly Valued range.

42.98

P/FCF

Transmedics Group Inc. (TMDX) has a current P/FCF of 42.98. The 5-year average P/FCF is -6385.59. The thresholds are as follows: Strongly Undervalued below -55088.79, Undervalued between -55088.79 and -30737.19, Fairly Valued between 17966.01 and -30737.19, Overvalued between 17966.01 and 42317.61, and Strongly Overvalued above 42317.61. The current Forward P/FCF of 42.98 falls within the Historic Trend Line -Fairly Valued range.

Transmedics Group Inc (TMDX) has a current Price-to-Book (P/B) ratio of 13.04. Compared to its 3-year average P/B ratio of 16.40 , the current P/B ratio is approximately -20.45% higher. Relative to its 5-year average P/B ratio of 13.41, the current P/B ratio is about -2.71% higher. Transmedics Group Inc (TMDX) has a Forward Free Cash Flow (FCF) yield of approximately 0.41%. Compared to its 3-year average FCF yield of -3.78%, the current FCF yield is approximately -110.96% lower. Relative to its 5-year average FCF yield of -4.37% , the current FCF yield is about -109.49% lower.

12.71

P/B

Median3y

16.40

Median5y

13.41

0.42

FCF Yield

Median3y

-3.78

Median5y

-4.37

Competitors Valuation Multiple

The average P/S ratio for TMDX's competitors is 3.61, providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX) exhibits a P/S ratio of 6.35, which is 75.80% above the industry average. Given its robust revenue growth of 37.68%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TMDX.O

Transmedics Group Inc

Integer Holdings Corp

Lantheus Holdings Inc

Merit Medical Systems Inc

Performance Decomposition

Market capitalization of TMDX decreased by 29.31% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 10.67 to 22.18.

The secondary factor is the Revenue Growth, contributed 37.68%to the performance.

Overall, the performance of TMDX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

37.68%

114.31M → 157.37M

Revenue Growth

107.87%

10.67 → 22.18

Margin Expansion

-174.86%

-78.65 → 58.88

P/E Change

-29.31%